Newsroom

Biotechnology

Explore the latest breakthroughs and trends in the Biotechnology sector with our newsroom. From cutting-edge innovations in gene therapy and biopharmaceuticals to advancements in medical research and regulatory updates, we provide essential insights into the scientific developments shaping the future of healthcare and life sciences.


Latest Press Releases

1169029 B.C. Ltd. Announces Completion of the Arrangement with HemaGenetics Technologies Corp. and Issuance of Shares in Furtherance of the Arrangement
Biotechnology

1169029 B.C. Ltd. Announces Completion of the Arrangement with HemaGenetics Technologies Corp. and Issuance of Shares in Furtherance of the Arrangement

January 22, 2019 6:20 PM

VANCOUVER, BC / ACCESSWIRE / January 22, 2019 / 1169029 B.C. Ltd. (the "Company") is pleased to announce that as a result of the completion of a plan of arrangement between the Company and HemaGenetics Technologies Corp. ("HGT") under the arrangement agreement entered into on June 26, 2018 between HGT, the Company, Mucho Cobre Resources Ltd. (formerly, 1169080 B.C. Ltd.), 1169032 B.C. Ltd., 1169071 B.C. Ltd., 1169077 B.C. Ltd., and...

Read more
Dyadic to Present at NobleCon XV
BiotechnologyCompany UpdateConferences

Dyadic to Present at NobleCon XV

January 22, 2019 10:00 AM

JUPITER, FL / ACCESSWIRE / January 22, 2019 / Dyadic International, Inc. (the ''Company'') (OTCQX: DYAI) today announced that its CEO, Mark Emalfarb will present at NobleConXV - Noble Capital Markets' Fifteenth Annual Investor Conference at the W Hotel, Fort Lauderdale, Florida - on Monday, January 28, 12:30 pm Eastern Standard Time. A high-definition, video webcast of the presentation will be available the following day on the Company's website...

Read more
HemaGenetics Announces Setting of the Effective Date & Record Date for the Plan of Arrangement with 1169029 B.C. Ltd.
BiotechnologyCompany Update

HemaGenetics Announces Setting of the Effective Date & Record Date for the Plan of Arrangement with 1169029 B.C. Ltd.

January 18, 2019 1:57 PM

VANCOUVER, BC / ACCESSWIRE / January 18, 2019 / HemaGenetics Technologies Corp. (the "Company") is pleased to announce that further to the previously announced arrangement under the arrangement agreement entered into on June 26, 2018 between the Company, Mucho Cobre Resources Ltd. (formerly, 1169080 B.C. Ltd.), 1169029 B.C. Ltd., 1169032 B.C. Ltd., 1169071 B.C. Ltd., 1169077 B.C. Ltd., and 1169082 B.C. Ltd. (the "Arrangement"), the Company has...

Read more
Dyadic Announces the Filing of Replacement Form 10 Registration Statement with SEC
BiotechnologyRegulatory

Dyadic Announces the Filing of Replacement Form 10 Registration Statement with SEC

January 15, 2019 8:40 AM

JUPITER, FL / ACCESSWIRE / January 15, 2019 / Dyadic International, Inc. (the "Company") ("OTCQX: DYAI) today announced that the Company has filed a replacement Registration Statement on Form 10-12G (the "Replacement Form 10") with the Securities and Exchange Commission (the "Commission"). On November 5, 2018, the Company filed its initial Form 10-12G (File No. 000-55264) (the "Initial Form 10"), which was withdrawn on January 2, 2019 in order...

Read more
Quanta Launches Proprietary Polarized CBD Product Lines
BiotechnologyProduct Announcements

Quanta Launches Proprietary Polarized CBD Product Lines

January 10, 2019 8:30 AM

Company discontinues licensing to CBD brands, sees larger upside in manufacturing its own product lines LOS ANGELES, CA / ACCESSWIRE / January 10, 2019 / Quanta, Inc. (OTC PINK: QNTA) an applied science company, focused on enhancing energy levels in plant matter, including hemp and cannabis, to increase performance within the human body, today announced that it will begin manufacturing its own line of polarized cannabidiol (CBD) products due to...

Read more
AYOXXA Signs Research Agreement in the Field of Ophthalmology With One of the Leading Pharmaceutical Companies
BiotechnologyPartnerships

AYOXXA Signs Research Agreement in the Field of Ophthalmology With One of the Leading Pharmaceutical Companies

January 7, 2019 10:45 AM

Agreement targets the development of low volume and high sensitivity multiplex assays for aqueous humor protein profiling for biomarker identification and validation in support of drug discovery in ophthalmology This collaboration reflects an initial phase of a multi study plan in the field of ophthalmology Further step to establish AYOXXA LUNARISTM system as the standard for biomarker identification and validation in translational...

Read more
Pressure BioSciences, Inc. Announces Commercial Launch of its Unique Biopharmaceuticals Contract Services Business
Biotechnology

Pressure BioSciences, Inc. Announces Commercial Launch of its Unique Biopharmaceuticals Contract Services Business

January 7, 2019 7:11 AM

Proprietary Technology Platform Offers Improved Manufacturing for Protein Therapeutic Candidates and Positions PBI to Service the $250 Billion Global Biopharmaceuticals Market SOUTH EASTON, MA / ACCESSWIRE / January 7, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"), a leader in the development and sale of enabling high pressure-based instruments, consumables, and related services for the worldwide life sciences...

Read more
Molecular Partners to Present at The 37th Annual J.P. Morgan Healthcare Conference
Biotechnology

Molecular Partners to Present at The 37th Annual J.P. Morgan Healthcare Conference

January 7, 2019 1:00 AM

Company to highlight recent progress on clinical DARPin® compounds, its oncology research strategy and to discuss the strategic collaboration with Amgen on MP0310 ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / January 7, 2019 / Molecular Partners AG (SWX: MOLN) (OTC PINK: MLLCF), a clinical-stage biotech company pioneering the use of DARPin® therapeutics* to treat serious diseases, today announced that it will present at the 37th Annual J.P....

Read more
Shanghai-Based Hexaell Biotech Secures 50 million RMB ($7.3 million) Series A Financing From Hyfinity Investments
BiotechnologyFinancing

Shanghai-Based Hexaell Biotech Secures 50 million RMB ($7.3 million) Series A Financing From Hyfinity Investments

January 3, 2019 9:00 AM

The funding will be used to support the clinical and CFDA registration of the hiHep cell engineering system and further accelerate Hexaell's research and development in liver diseases and cell engineering pipeline SHANGHAI, CHINA / ACCESSWIRE / January 3, 2019 / Hexaell Biotechnologies Ltd, a Shanghai-based technology company specializing in bio-artificial liver organ based on hiHep cell engineering systems, closed the Series A round of 50...

Read more
Dyadic Announces Update Regarding Initial Form 10 Registration Statement Filing with SEC
BiotechnologyCompany Update

Dyadic Announces Update Regarding Initial Form 10 Registration Statement Filing with SEC

January 2, 2019 6:05 PM

JUPITER, FL / ACCESSWIRE / January 2, 2019 / Due to the federal government shutdown, the Securities and Exchange Commission (the "Commission") has not completed its review of Dyadic International, Inc's. (OTCQX: DYAI) (the "Company") Registration Statement on Form 10-12G (File No. 000-55264), filed on November 5, 2018 (the "Registration Statement"). As a result, on January 2, 2019, the Company notified the Commission of its desire to prevent the...

Read more
Early Warning Report under National Instrument 62-103
BiotechnologyRegulatory

Early Warning Report under National Instrument 62-103

December 31, 2018 9:00 AM

NORTH YORK, ON / ACCESSWIRE / December 31, 2018 / On December 19, 2018, Tree of Knowledge International Corp. (the "Corporation") completed an offer to purchase all of the outstanding securities of Asterion Bio Med Inc. ("Asterion") on the basis of 2.1894 common shares of the Corporation (the "Exchange Ratio") for each common share of Asterion (the "Offer"). As a result, Asterion became a wholly owned subsidiary of the Corporation. In addition...

Read more
ZIVO Nutritional Efficacy Study for Poultry is Successful, Confirms Production Methods and Health Benefits
BiotechnologyCompany Update

ZIVO Nutritional Efficacy Study for Poultry is Successful, Confirms Production Methods and Health Benefits

December 19, 2018 9:55 AM

KEEGO HARBOR, MI / ACCESSWIRE / December 19, 2018 / ZIVO Bioscience, Inc. (OTCQB: ZIVO) a biotech/agtech R&D company engaged in the commercialization of nutritional products derived from its proprietary algal strains, announces today that preliminary data analysis from its most recent poultry nutritional efficacy study show positive results that confirm the successes of previous poultry efficacy studies conducted in partnership with NutriQuest,...

Read more
Passage of U.S. Farm Bill a Major Milestone for EastWest’s Long Term Hemp Strategy
Biotechnology

Passage of U.S. Farm Bill a Major Milestone for EastWest’s Long Term Hemp Strategy

December 19, 2018 9:00 AM

EastWest BioScience Negotiating Major Strategic Hemp and CBD Opportunities. VANCOUVER, BC / ACCESSWIRE / December 19, 2018 / EastWest Bioscience Inc. (the "Company" or "EastWest") (TSX-V: EAST) is hopeful for an early Christmas present with continuing progress of the U.S. Farm Bill. The federal legalization of hemp in the US, once passed, opens up significant opportunities for EastWest to follow through on its long held strategic plans to market...

Read more
Major Cancer Research Center Reports Pressure BioSciences' PCT Platform Could Play Major Role in Improving Cancer Diagnosis and Treatment
BiotechnologyCompany Update

Major Cancer Research Center Reports Pressure BioSciences' PCT Platform Could Play Major Role in Improving Cancer Diagnosis and Treatment

December 18, 2018 9:32 AM

Publication Cites Significant Benefits from Using the PCT Platform in the Analysis of Cancer Tissue Biopsies SOUTH EASTON, MA / ACCESSWIRE / December 18, 2018 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") is a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences and other industries. The Company today announced that...

Read more
Pressure BioSciences, Inc. to Host Business Update on Wednesday, December 19th at 4:30 PM EST
BiotechnologyCompany Update

Pressure BioSciences, Inc. to Host Business Update on Wednesday, December 19th at 4:30 PM EST

December 17, 2018 11:25 AM

Update to Include Discussions on Recent Progress, Accomplishments, and Enhancements in All Three Platform Technologies; Commercialization and Strategic Partnership Efforts; Personnel Changes; and Q42018 & FY2019 Guidance SOUTH EASTON, MA / ACCESSWIRE / December 17, 2018 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to provide an update on recent progress,...

Read more
Qrons Extends Services Agreement with Ariel University for Additional Year
BiotechnologyCompany Update

Qrons Extends Services Agreement with Ariel University for Additional Year

December 17, 2018 9:00 AM

Agreement Will Facilitate Completion of First Candidate Product to Treat Traumatic Brain Injuries MIAMI, FL / ACCESSWIRE / December 17, 2018 / Qrons Inc. (OTC PINK: QRON) ("Qrons " or the "Company"), a preclinical biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a laser focus on treating traumatic brain injuries ("TBIs"), announced today that it has renewed its Services Agreement with Ariel...

Read more
Eastwest BioScience Receives Multiple Purchase Orders with Global Retailer The TJX Companies Inc (NYSE: TJX) for Canada Wide Distribution
Biotechnology

Eastwest BioScience Receives Multiple Purchase Orders with Global Retailer The TJX Companies Inc (NYSE: TJX) for Canada Wide Distribution

December 13, 2018 9:00 AM

VANCOUVER, BC / ACCESSWIRE / December 13, 2018 / EastWest Bioscience (the "Company" or "EastWest") (TSX.V: EAST) announces that the Company is processing purchasing orders for its hemp based consumer goods through global retailer The TJX Companies, Inc (NYSE:TJX), the leading mass retailer of apparel and home fashions in the U.S. and worldwide. TJX is a global retail giant that has built a distinguishable and competitive brand with a strong...

Read more
American CryoStem to file Investigational New Drug Application with FDA
BiotechnologyCompany Update

American CryoStem to file Investigational New Drug Application with FDA

December 13, 2018 6:30 AM

EATONTOWN, NJ / ACCESSWIRE / December 13, 2018 / American CryoStem Corporation (OTC PINK: CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular products and technologies for the Regenerative and Personalized Medicine industries, today announced that it has completed its Pre-IND discussions with the FDA concerning its ongoing work to file an Investigational New Drug Application (IND)...

Read more
Mymetics Virosomes Successful in Allergy Proof-of-Concept Study
Biotechnology

Mymetics Virosomes Successful in Allergy Proof-of-Concept Study

December 13, 2018 2:00 AM

Success criteria met: Bet v 1 COP-virosomes showed no IgE induction, favorable TH1 response and were well tolerated in mice study Anergis has time limited exclusive option to license Mymetics' virosome technology in the field of allergies EPALINGES, SWITZERLAND / ACCESSWIRE / December 13, 2018 / Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life...

Read more
EastWest Announces Change of Directors
Biotechnology

EastWest Announces Change of Directors

December 11, 2018 4:40 PM

VANCOUVER, BC / ACCESSWIRE / December 11, 2018 / EastWest Bioscience (formerly Harbour Star Capital Inc.) (the "Company" or "EastWest") (TSXV: EAST) announces that Mr. Mohammad Fazil has resigned as a director effective as of December 4, 2018, the Company wishes to thank Mr. Fazil for his years of service to Harbour Star Capital Inc. and assistance following completion of the qualifying transaction, as set out in the press release issued...

Read more

Join the thousands of ACCESS Newswire customers today who are getting millions of views on their news.


Check out our flexible subscription and pay as you go pricing

and packages.

Use Code NEWS10 for 10% off  of your first purchase.


Latest Blog Posts

Visit our blogs for press release tips, media engagement

Strategies, and Product Comparisons.

Executive delivering prepared remarks from an earnings call script
By Jennifer Hammers • July 9, 2026
How to write earnings call prepared remarks that land — structure, length, the safe-harbor open, non-GAAP language, and building remarks around your strategy.
IR
By Brian Balbirnie • July 8, 2026
A practical earnings call preparation checklist for IR teams — the two-week runway, consensus, logistics, Q&A prep, and Reg FD-clean disclosure timing.
ACCESS Newswire guide on AI investor relations — how AI assistants read company earnings disclosures
By Jennifer Hammers • July 6, 2026
AI assistants read your earnings within minutes. Learn how IR teams make disclosures AI-readable — and how the LLM Citation Score measures your visibility.
What does Meltwater cost in 2026, and what are the alternatives? Meltwater resells press release dis
By Jennifer Hammers • June 22, 2026
What does Meltwater cost in 2026, and what are the alternatives? See how ACCESS Newswire compares on distribution, data, and price.
A logo for accesswire next to a logo for rack
By Jennifer Hammers • June 21, 2026
Compare Muck Rack vs ACCESS Newswire on pricing, features, and alternatives. See how ACCESS Newswire adds distribution, pitching, and analytics.
A blue and white logo with a check mark next to it
By Jennifer Hammers • June 19, 2026
Compare Business Wire vs ACCESS Newswire on pricing and capabilities — and how ACCESS delivers comparable reach at a fraction of the cost.
Show More




Discover the news
by Industry:


Need help with your PR Strategy?
Learn more about our
professional PR Services today:

.MEDIA PRO 
Want to get noticed
by the Media but don’t
know how? 

.TOTAL PRO

Need full support to 

Optimize your PR

Efforts?